CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

TerminatedOBSERVATIONAL
Enrollment

87

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 28, 2015

Study Completion Date

May 28, 2015

Conditions
Crohn's Disease
Interventions
DRUG

natalizumab

Administered as specified in the TOUCH Prescribing Program

Trial Locations (36)

10021

Research site, New York

11021

Research site, Great Neck

11042

Research site, Lake Success

21201

Research site, Baltimore

27599

Research site, Chapel Hill

27607

Research site, Raleigh

28207

Research site, Charlotte

30342

Research site, Atlanta

32610

Research site, Gainesville

32789

Research site, Winter Park

33136

Research site, Miami

37232

Research site, Nashville

40202

Research site, Louisville

40536

Research site, Lexington

41017

Research site, Crestview Hills

44195

Research site, Cleveland

45219

Research site, Cincinnati

48084

Research site, Troy

48109

Research site, Ann Arbor

55446

Research site, Plymouth

55905

Research site, Rochester

65201

Research site, Columbia

76051

Research site, Grapevine

77030

Research site, Houston

85260

Research site, Scottsdale

92056

Research site, Oceanside

94115

Research site, San Francisco

98405

Research site, Tacoma

06518

Research site, Hamden

06106

Research site, Hartford

02114

Research site, Boston

02215

Research site, Boston

03756

Research site, Lebanon

08234

Research site, Egg Harbor

02904

Research site, Providence

00935

Research site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY